These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31691587)

  • 1. Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].
    Naidoo A; Sibbald C; Fleming PJ; Piguet V
    J Cutan Med Surg; 2020; 24(1):73-78. PubMed ID: 31691587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for pityriasis rubra pilaris treatment: A review of the literature.
    Napolitano M; Abeni D; Didona B
    J Am Acad Dermatol; 2018 Aug; 79(2):353-359.e11. PubMed ID: 29609014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
    Maloney NJ; Hisaw LD; Worswick S
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy.
    Müller H; Gattringer C; Zelger B; Höpfl R; Eisendle K
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S65-70. PubMed ID: 19119128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pityriasis rubra pilaris type I: a systematic review.
    Engelmann C; Elsner P; Miguel D
    Eur J Dermatol; 2019 Oct; 29(5):524-537. PubMed ID: 31789274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies of pityriasis rubra pilaris: a systematic review.
    Kromer C; Sabat R; Celis D; Mössner R
    J Dtsch Dermatol Ges; 2019 Mar; 17(3):243-259. PubMed ID: 30520557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists.
    Petrof G; Almaani N; Archer CB; Griffiths WA; Smith CH
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e131-5. PubMed ID: 22324561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pityriasis rubra pilaris: a case series of 28 patients.
    Kromer C; Lippert U; Schön MP; Mössner R
    Eur J Dermatol; 2020 Oct; 30(5):569-579. PubMed ID: 33021474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
    Ivanova K; Itin P; Haeusermann P
    Dermatology; 2012; 224(2):120-5. PubMed ID: 22508269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
    Boyd AH; Polcari IC
    Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
    Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
    Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.
    Liang JY; Ye RX; Tian X; Zhang SQ; Zhang XB
    Dermatol Ther; 2020 Nov; 33(6):e14097. PubMed ID: 32725719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of refractory pityriasis rubra pilaris: challenges and solutions.
    Moretta G; De Luca EV; Di Stefani A
    Clin Cosmet Investig Dermatol; 2017; 10():451-457. PubMed ID: 29184428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pityriasis rubra pilaris].
    Wollina U
    Hautarzt; 2012 Aug; 63(8):655-61; quiz 662. PubMed ID: 22825756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.
    Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B
    J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series.
    Garcovich S; Di Giampetruzzi AR; Antonelli G; Garcovich A; Didona B
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):881-4. PubMed ID: 20002243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
    Gómez M; Ruelas ME; Welsh O; Arcaute HD; Ocampo-Candiani J
    J Drugs Dermatol; 2007 Mar; 6(3):337-9. PubMed ID: 17373198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital.
    Ringin S; Baker CS; Foley P; Daniel BS
    Dermatol Ther; 2021 Nov; 34(6):e15128. PubMed ID: 34505752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.
    Cook E; Tran KW; Kollipara S; Tarbox M; Akin R
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.